A study from the Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; and Howard Hughes Medical Institute, New York, New York, USA shows that “Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis.” This study was published in the 30 March 2015 issue of the Journal “Nature Genetics” (the no.1 journal in Genetics with an impact factor of 29.648) by Prof Lowe SW, Zhao Z and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myeloid leukemia: Deltex1 increases the expression of tumor suppressor protein SPRY4 via down regulation of its target gene.
Significance: This study suggests, for the first time, that Deltex1, by decreasing the expression of its target gene, it may increase the expression of tumor suppressor protein SPRY4. Thereby, it may inhibit the progression of a number of human cancers, including Myeloid leukemia. Thus, pharmacological formulations encompassing “Deltex1 activators” may be used to inhibit the progression of human caners.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Myeloid leukemia: Deltex1 increases the expression of tumor suppressor protein SPRY4 via down regualation of its target gene, 7/April/2015, 8.26 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How Deltex1 increases the expression of SPRY4